September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Supra-molecular structure of a Lumican derived peptide amphiphile enhances collagen-stimulating activity in corneal fibroblasts
Author Affiliations & Notes
  • Che John Connon
    Faculty of Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
  • Merlin Walter
    Faculty of Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
  • Ashkan Dehsorkhi
    Chemistry, University of Reading, Reading, United Kingdom
  • Ian Hamley
    Chemistry, University of Reading, Reading, United Kingdom
  • Footnotes
    Commercial Relationships   Che Connon, None; Merlin Walter, None; Ashkan Dehsorkhi, None; Ian Hamley, None
  • Footnotes
    Support  EPSRC EP/L020599/1
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Che John Connon, Merlin Walter, Ashkan Dehsorkhi, Ian Hamley; Supra-molecular structure of a Lumican derived peptide amphiphile enhances collagen-stimulating activity in corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Peptide amphiphiles (PA) are a class of molecules that combine the structural features of amphiphilic surfactants with the functions of bioactive peptides that assemble into a variety of nanostructures above a critical aggregation concentration (CAC). Here we have investigated the effects of a PA based upon a 13-residue sequence, YEALRVANEVTLN, derived from the C-terminus of the proteoglycan Lumican, attached to a C16 hydrophobic tail (lum-PA). In particular, we focused on the enhanced bioactivity of the lum-PA in supra-molecular form and its mode of action on human corneal fibroblasts (HCF).

Methods : The lum-PA was dissolved in water below (0.025 wt%) or above (0.1 wt%) its CAC thus existing as a solution of either monomeric molecules or aggregated nanotapes. Further dilution to 0.00125 wt% and 0.0025 wt% allowed the effects of supra-molecular assembly to be tested. Circular dichroism (CD) was performed on the lum-PA solutions.
HCF were extracted from donor corneal-rings and maintained in DMEM/F12, 5% FBS, 1 mM ascorbic acid, then with serum-free media (SFM) supplemented with 1% ITS 3 days prior to experiments. Subsequently 1x104 cells / well were cultured in 0.00125 wt% or 0.0025 wt% solutions of lum-PA in SFM for 7 days or 3 weeks. Cell proliferation and collagen production was quantified by alamarBlue® and Sirius red assays. These experiments were repeated in the presence of an ALK inhibitor SB 431542 at 0.5μM.

Results : CD confirmed the presence of supra-molecular form following dilution. HCF cultured in 0.0025 wt% and 0.00125 wt% lum-PA showed normal morphology and comparable viability after 7 days in monomeric or diluted-aggregated lum-PA. HCF produced significantly greater (p<0.05) total amounts of collagen compared to the control. Over 21 days, both total mass of collagen and collagen per cell significantly increased (p<0.05) in response to the diluted-aggregated lum-PA solutions. SB 431542 inhibited collagen production in the presence of diluted-aggregated lum-PA.

Conclusions : A peptide amphiphile has been designed using a biologically active peptide sequence from the C-terminal domain of lumican (lum-PA). The lum-PA’s supra-molecular organisation is not only maintained upon subsequent dilution, but its nano-structure produces a significant stimulatory effect on HCF’s collagen production which appears to be mediated by ALK receptor activity.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×